Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study
Phase of Trial: Phase 0
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs PI 2620 (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Diagnostic use; First in man
- 04 Jun 2018 Status changed from not yet recruiting to recruiting.
- 23 May 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
- 02 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.